Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM ESTCompany ParticipantsSteve Chapman - CEO & ...

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...

Roche recently announced positive Phase 3 trial results for its breast cancer therapy, giredestrant, which operates through a mechanism that directly parallels Olema Pharmaceuticals’ lead candidate, ...

Roche's giredestrant has experienced a notable turnaround after initial challenges in phase 2 trials. The company previously reported a phase 3 win for the drug in September, which was further ...

Roche announced positive phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor ...

Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor Olema Pharmaceuticals Inc. Made public were positive phase III data from ...

According to DataM Intelligence AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics ...

FDA approves Poherdy, the first interchangeable biosimilar for Perjeta, enhancing competition in HER2-positive breast cancer ...

Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.